Henrikson N B, Burke W, Veenstra D L
Institute for Public Health Genetics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA.
Pharmacogenomics J. 2008 Apr;8(2):85-9. doi: 10.1038/sj.tpj.6500457. Epub 2007 May 8.
Some pharmacogenetic tests may provide ancillary disease risk information. To evaluate evidence and assess the social and policy implications of ancillary disease risk information associated with candidate pharmacogenetic variants, We conducted a literature search and abstract review of disease susceptibility studies for each of 42 gene variants potentially associated with drug response. Twenty-two variants (53%) had suggested association with disease risk in at least two studies, and sixteen (38%) were for diseases other than the pharmacogenetic indication. Seven variants (16%) were associated with risk for at least two different diseases. Pharmacogenetic tests have the potential to provide ancillary disease risk information, and this potential should be considered as pharmacogenetic tests are brought into clinical use. Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information.
一些药物遗传学检测可能会提供辅助疾病风险信息。为了评估证据，并评估与候选药物遗传学变异相关的辅助疾病风险信息的社会和政策影响，我们对42种可能与药物反应相关的基因变异中的每一种进行了疾病易感性研究的文献检索和摘要审查。在至少两项研究中，22种变异（53%）显示与疾病风险相关，16种（38%）与药物遗传学适应症以外的疾病相关。7种变异（16%）与至少两种不同疾病的风险相关。药物遗传学检测有可能提供辅助疾病风险信息，在将药物遗传学检测应用于临床时应考虑到这种可能性。每种检测的影响各不相同，但应在一个概述辅助信息潜在影响的框架内对检测进行单独评估。
